NEWS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Immune Design to Present at Upcoming Investor Conferences
SEATTLE and SOUTH SAN FRANCISCO, Calif., Feb. 10, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that Carlos Paya, M.D., Ph.D., President and Chief Executive Officer, will present at two upcoming investor
View HTML
Toggle Summary Immune Design Provides Update from Two Discovery Platforms: DC-tropic ZVex Delivering Multiple Tumor Antigens (Conserved and Neo-Antigens) and G100 For Intratumoral Immunotherapy
SEATTLE and SOUTH SAN FRANCISCO, Calif., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Immune Design, a clinical-stage immunotherapy company focused on oncology, today announced new data that highlight the broad product reach potential of both its Specific Antigen and Endogenous Antigen/Intratumoral
View HTML
Toggle Summary New Immune Design Data Highlights Expanded Product Potential of ZVex® Platform at the 2016 SITC Annual Meeting
Introduces multiple-genome expression and new prime-boost approaches
View HTML
Toggle Summary Immune Design Reports Third Quarter 2016 Financial Results and Provides Corporate Update
Company conference call at 1:30 p.m. PT today
View HTML
Toggle Summary Immune Design to Report Third Quarter 2016 Financial Results & Present at Upcoming Investor Conference
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will report third quarter 2016 financial results after the close of U.S. financial markets on Wednesday, Nov.
View HTML
Toggle Summary Immune Design Appoints Sergey Yurasov, M.D., Ph.D. as Senior Vice President of Clinical Development and Chief Medical Officer
SEATTLE and SOUTH SAN FRANCISCO, Calif., Oct. 04, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced the appointment of Sergey Yurasov, M.D., Ph.D. as Senior Vice President of Clinical Development and Chief Medical
View HTML
Toggle Summary Immune Design Announces Advancement of First GLAAS™-based Allergy Program into Clinical Development
Partner Sanofi commences dosing in peanut allergy Phase 1 trial leveraging GLAAS
View HTML
Toggle Summary Immune Design Prices Public Offering of Common Stock
SEATTLE and SOUTH SAN FRANCISCO, Calif., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Immune Design Corp. (Nasdaq:IMDZ) announced today the pricing of an underwritten public offering of 4,800,000 shares of its common stock at a price to the public of $6.25 per share.
View HTML
Toggle Summary Immune Design Announces Proposed Public Offering of Common Stock
SEATTLE and SOUTH SAN FRANCISCO, Calif., Sept. 14, 2016 (GLOBE NEWSWIRE) -- Immune Design Corp. (Nasdaq:IMDZ) announced today that it plans to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the proposed offering are to be sold by Immune Design.
View HTML
Toggle Summary Immune Design Reports Second Quarter 2016 Financial Results and Provides Corporate Update
Company conference call at 1:30 p.m. PT today
View HTML